My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 530549 | NSE: SHILPAMED | Pharmaceuticals & Drugs | Small Cap
1. Is Shilpa Medicare Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.
2. Is Shilpa Medicare Ltd undervalued or overvalued?
The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
3. Is Shilpa Medicare Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 17.1% | 11.8% | 15.4% | 10.8% | 8% | 6.8% | 9.6% | 5.2% | 3.3% | -0% | - | ||
| Value Creation Index ⓘ | 0.2 | -0.2 | 0.1 | -0.2 | -0.4 | -0.5 | -0.3 | -0.6 | -0.8 | -1.0 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 571 | 614 | 716 | 779 | 789 | 733 | 908 | 901 | 1,146 | 1,050 | 1,049 | ||
| YoY Gr. Rt. % | - | 7.4% | 16.7% | 8.8% | 1.2% | -7% | 23.8% | -0.8% | 27.1% | -8.3% | - | ||
| Adj EPS ⓘ | 11.1 | 9.4 | 14.4 | 13 | 12 | 10.7 | 17.7 | 10.9 | 5.9 | -4.9 | -3.7 | ||
| YoY Gr. Rt. % | - | -15.8% | 53.8% | -10.1% | -7.6% | -10.6% | 65.6% | -38.4% | -46.3% | -182.6% | - | ||
| BVPS (₹) ⓘ | 53.9 | 70.9 | 82.9 | 123.2 | 133.1 | 146.9 | 163.1 | 181.4 | 209.9 | 205.4 | 205.8 | ||
| Adj Net Profit ⓘ | 81.9 | 72.2 | 111 | 104 | 97.7 | 87.3 | 145 | 89 | 51 | -42.1 | -32 | ||
| Cash Flow from Ops. ⓘ | 70 | 68.8 | 129 | 37.5 | 44.9 | 147 | 124 | 46.9 | 105 | 226 | - | ||
| Debt/CF from Ops. ⓘ | 1.7 | 2.7 | 0.7 | 6.4 | 4.3 | 1.3 | 3.1 | 18 | 6.5 | 3.5 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 7% | 5.9% | 5% | -8.3% | ||||||||
| Adj EPS ⓘ | -191.2% | -183.5% | -164.9% | -182.6% | ||||||||
| BVPSⓘ | 16% | 9.1% | 8% | -2.1% | ||||||||
| Share Price | 15.5% | -2.7% | -14.9% | -1.1% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 22.8 | 15.3 | 18.7 | 12.8 | 9.4 | 7.7 | 11.4 | 6.3 | 3.1 | -2.3 | -1.8 | |
| Op. Profit Mgn % ⓘ | 21.3 | 20.6 | 22.5 | 20.8 | 19.2 | 21.1 | 23.6 | 19.1 | 17.4 | 8.4 | 12.4 | |
| Net Profit Mgn % ⓘ | 14.2 | 11.6 | 15 | 12.9 | 12.1 | 11.5 | 15.8 | 9.7 | 4.4 | -3.9 | -3.1 | |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.6 | 0.4 | 0.5 | - | |
| Working Cap Days ⓘ | 135 | 158 | 158 | 193 | 237 | 266 | 230 | 286 | 280 | 308 | 0 | |
| Cash Conv. Cycle ⓘ | 40 | 56 | 59 | 84 | 116 | 141 | 126 | 170 | 164 | 186 | 0 | |
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years 4.97%
Sales growth is not so good in last 4 quarters at -9.39%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -5.2 | -3.7 |
| TTM Sales (₹ Cr.) | 271 | 1,049 |
| BVPS (₹.) ⓘ | 244.9 | 205.8 |
| Reserves (₹ Cr.) ⓘ | 2,117 | 1,777 |
| P/BV ⓘ | 1.44 | 1.72 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 222.40 / 391.85 |
| All Time Low / High (₹) | 0.39 / 786.75 |
| Market Cap (₹ Cr.) | 3,070 |
| Equity (₹ Cr.) | 8.7 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 42 |
| Pledged * | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 | 1.38 | 12.90 | 12.90 |
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh. Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.
Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.
Product range of the company includes:
Oncology AP's
General APIs
PRODUCTS UNDER DEVELOPMENT (Oncology)
NUTRITIONAL SUPPLEMENTS
DRUG INTERMEDIATES
Awards & Achievements:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
